MX2024004302A - Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1. - Google Patents

Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1.

Info

Publication number
MX2024004302A
MX2024004302A MX2024004302A MX2024004302A MX2024004302A MX 2024004302 A MX2024004302 A MX 2024004302A MX 2024004302 A MX2024004302 A MX 2024004302A MX 2024004302 A MX2024004302 A MX 2024004302A MX 2024004302 A MX2024004302 A MX 2024004302A
Authority
MX
Mexico
Prior art keywords
methods
effecting
administering
npr1
hemodynamic change
Prior art date
Application number
MX2024004302A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dunn
Aaron Kithcart
Benjamin Adam Olenchock
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024004302A publication Critical patent/MX2024004302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004302A 2021-10-11 2022-10-11 Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1. MX2024004302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (1)

Publication Number Publication Date
MX2024004302A true MX2024004302A (es) 2024-06-19

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004302A MX2024004302A (es) 2021-10-11 2022-10-11 Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1.

Country Status (12)

Country Link
US (2) US20240327539A1 (enExample)
EP (1) EP4415820A1 (enExample)
JP (1) JP2024537284A (enExample)
KR (1) KR20240099275A (enExample)
CN (1) CN118159290A (enExample)
AU (1) AU2022363841A1 (enExample)
CA (1) CA3234238A1 (enExample)
CL (1) CL2024001071A1 (enExample)
CO (1) CO2024005662A2 (enExample)
IL (1) IL311917A (enExample)
MX (1) MX2024004302A (enExample)
WO (1) WO2023064769A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024542823A (ja) 2021-12-06 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US11066469B2 (en) * 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
JP2024537284A (ja) 2024-10-10
AU2022363841A1 (en) 2024-03-28
KR20240099275A (ko) 2024-06-28
EP4415820A1 (en) 2024-08-21
CA3234238A1 (en) 2023-04-20
US20240327539A1 (en) 2024-10-03
US20250034279A1 (en) 2025-01-30
CL2024001071A1 (es) 2024-12-06
IL311917A (en) 2024-06-01
CN118159290A (zh) 2024-06-07
CO2024005662A2 (es) 2024-05-10
WO2023064769A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2024004302A (es) Metodos para realizar un cambio hemodinamico mediante la administracion de un anticuerpo anti-npr1.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
PE20230415A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
MY207780A (en) Anti-epha4 antibody
PH12021552162A1 (en) Liquid composition comprising antibody of human interleukin-4 receptor alpha
SG11201904692QA (en) Novel polypeptide and method of producing imp using the same
NZ778293A (en) Anti-clec2d antibodies and methods of use thereof
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
TWD219806S (zh) 醫療注射器的部件
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
PH12021552521A1 (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
PH12020551985A1 (en) Anti-human tlr7 antibody
MX2022016494A (es) Anticuerpos anti-il13ra2.
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
MX2022003266A (es) Dosis para anticuerpos anti-triptasa.
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma
TWD231433S (zh) 泵浦
SA522441781B1 (ar) Tlr4 مادة مساعدة ذات نشاط معضد لـ
MX2023001491A (es) Moleculas de union a gp130 y metodos de uso.
WO2019236747A3 (en) Cyclic peptide compounds and methods of use thereof
TWD199374S (zh) 醫療黏著劑注膠器